NASDAQ$TSHA
Taysha Gene Therapies Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2021, and provided a corporate update.
Taysha Gene Therapies reported a net loss of $32.0 million, or $0.87 per share, for the first quarter ended March 31, 2021. As of March 31, 2021, Taysha had $228.7 million in cash and cash equivalents.
- TSHA-120 program demonstrated clear arrest of disease progression and long-term durability at therapeutic dose levels in patients with giant axonal neuropathy (GAN).
- Expects to have five programs in Phase 1/2 trials in the second half of 2021, including GAN, GM2 gangliosidosis, CLN1 disease, Rett syndrome and SURF1-associated Leigh syndrome.
- Positive preclinical data for TSHA-102 in Rett syndrome provided quantitative evidence of miRARE’s ability to exhibit genotype-dependent regulation of MECP2 gene expression.
- Treatment with TSHA-102 resulted in a statistically significant survival extension by 56% in 4-5 week-old knockout Rett mice.
Headline financials
Revenue & EPS history
Taysha Gene Therapies · Revenue · Quarterly
$0
Forward guidance
Taysha Gene Therapies anticipates several milestones across its programs and corporate development in 2021.
Tailwinds
- Report clinical data for TSHA-120 from the 3.5x1014 total vg dose cohort in the second half of 2021.
- Engage with major regulatory agencies to discuss the approval pathway and provide a regulatory update by year-end 2021 for TSHA-120.
- Report preliminary Phase 1/2 safety and biomarker data (Queen’s University trial) in the second half of 2021 for TSHA-101.
- Submit an Investigational New Drug (IND) application in the U.S. in the second half of 2021 for TSHA-101.
- Initiate a Phase 1/2 clinical trial in the U.S. in the second half of 2021 for TSHA-101.
Headwinds
- No specific negative aspects were explicitly mentioned in the provided text. Therefore, this section is based on potential risks and uncertainties inherent in the biotechnology industry.
- Clinical trial delays or failures could impact the timeline for bringing therapies to market.
- Regulatory hurdles and the potential for non-approval of product candidates.
- Manufacturing challenges in scaling up production of gene therapies.
- Competition from other companies developing treatments for similar diseases.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
+10.9%
Avg return
Earnings day
+11.7%
Avg return
5 days after
+18.2%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+195.0%
Q2 2023
Best reaction
-16.0%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.5% | -6.3% | — | |
| Q1 2026 | +0.6% | -1.6% | -20.9% | |
| Q3 2025 | -5.9% | -8.9% | +18.3% | |
| Q2 2025 | +5.4% | +6.5% | +17.4% | |
| Q1 2025 | +8.1% | +23.6% | +7.2% | |
| Q4 2024 | -4.7% | -4.7% | +13.5% | |
| Q3 2024 | -5.0% | -4.6% | -13.4% | |
| Q2 2024 | +9.1% | +7.7% | +11.0% | |
| Q1 2024 | +29.6% | +28.7% | +73.7% | |
| Q4 2023 | +39.0% | +52.6% | +13.1% | |
| Q3 2023 | +26.3% | +27.8% | +16.5% | |
| Q2 2023 | +195.0% | +159.8% | +312.7% | |
| Q1 2023 | -10.5% | -7.7% | +14.7% | |
| Q4 2022 | -6.5% | +14.8% | -3.9% | |
| Q3 2022 | -5.5% | +9.0% | +2.5% | |
| Q2 2022 | -16.0% | -16.4% | -29.9% | |
| Q1 2022 | -4.1% | -19.5% | -12.5% | |
| Q4 2021 | +3.1% | +8.5% | -40.5% | |
| Q3 2021 | +0.2% | -3.1% | -9.3% | |
| Q2 2021 | +0.7% | -2.6% | +20.1% | |
| Q1 2021 | -0.7% | +2.0% | +19.9% | |
| Q4 2020 | -7.2% | -0.2% | -19.9% | |
| Q3 2020 | +2.2% | +4.0% | +10.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro